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ABSTRACT 
Previous analyses of rearranged immunoglobulin (Ig) variable genes 
(VDJs) concluded that the mechanism of Ig somatic hypermutation 
(SHM) involves the Ig pre-mRNA acting as a copying template 
resulting in characteristic strand-biased somatic mutation patterns at 
A:T and G:C base pairs. We have since analysed cancer genome data 
and found the same mutation strand-biases, in toto or in part, in non-
lymphoid cancers. Here we have analysed somatic mutations in a 
single well characterised gene TP53. Our goal is to understand the 
genesis of the strand-biased mutation patterns in TP53 - and in 
genome-wide data - that may arise by "endogenous" mechanisms as 
opposed to adduct-generated DNA-targeted strand-biased mutations 
caused by well characterised "external" carcinogenic influences in 
cigarette smoke, UV-light and certain dietary components.  The 
underlying strand-biased mutation signatures in TP53, for many non-
lymphoid cancers, bear a striking resemblance to the Ig SHM pattern. 
A similar pattern can be found in genome-wide somatic mutations in 
cancer genomes that have also mutated TP53. The analysis implies a 
role for base-modified RNA template intermediates coupled to reverse 
transcription in the genesis of many cancers. Thus Ig SHM may be 
inappropriately activated in many non-lymphoid tissues via hormonal 
and/or inflammation-related processes leading to cancer. 
   3 
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A major goal of this paper is to provide an explanation of the origin of 
the main strand-biased mutation signatures observed in the TP53 
tumor suppressor gene in the many tumors likely to arise by 
"endogenous" mutation processes : that is to say, those cancers not 
caused by well known exogenous mechanisms such as exposure to 
carcinogens in tobacco smoke (Benzo(a)pyrene, G-to-T), toxins in 
food contamination (Aflatoxin B1, G-to-T; Aristolochic acid, A-to-T) or 
UV radiation in sun exposure  causing DNA photoproducts such as 
cyclobutane pyrimidine dimers, C-to-T; reviewed in Soussi [1].   The 
TP53 mutation pattern in "All Breast Cancers" has been chosen as 
representative of the TP53 "endogenous pattern" as this mutation 
pattern appears to arise in a tissue "least accessible to carcinogens in 
tobacco smoke" or directly exposed to such exogenous carcinogens, 
see Hainaut and Pfeifer [2]. There is also a large number of TP53 
point mutations in this tissue category (>1000), similar to the 
numbers in "All Lung Cancers", the major comparator in the analysis. 
Further, this basic "endogenous" pattern is evident in many tumors 
outside of lung, head, neck and oesophagus.  All of these can be 
considered as "directly accessible to tobacco smoke carcinogens". 
This choice is made despite the known complexity of breast cancer in 
both aetiology and the diversity of histological subtypes [1] as a 
similar pattern is evident in mutated TP53 variants in "All Bladder   5 
Cancers" which are likely to be more directly exposed to tobacco 
smoke-derived carcinogenic metabolites in urine.  
   Our analysis shows that the underlying "endogenous" strand-
biased mutation signatures in TP53, for many different non-lymphoid 
cancers, bear a striking resemblance to the Ig SHM pattern. This 
allows inferences to be drawn about the mechanistic role of TP53-
mediated DNA repair regulation and base-modified RNA template 
intermediates coupled to reverse transcription in the genesis of many 
cancers. It is also consistent with the view that the normally tightly 
regulated mutation processes targeting VDJ genes in B lymphocytes 
may, following further loss of DNA damage response regulation by 
TP53, be inappropriately turned on in non-lymphoid tissues, for 
example by hormonal and/or inflammation-related processes, leading 
to cancer.  
   
 
BACKGROUND 
 
Caveat and writing strategy: The writing strategy of this review is 
to provide as clear an introduction as possible concerning what is 
currently known of the immune system's somatic mutation 
mechanism as we believe that this mechanism is relevant to 
understanding the role of somatic mutations in the pathology of   6 
cancer.  This is an unexplored topic for most scientists, particularly in 
the field of cancer biology although it is very topical now given 
renewed interest in the regulation of inflammatory responses 
initiating both somatic mutations and thus cancer (see later). 
However there is a caveat to this analysis that should be highlighted 
right at the start: strand-biased mutation spectrums although very 
informative with strong inferential value with respect to molecular 
mechanisms provide little information about the initial events that 
precede malignant transformation as malignant cells grow rapidly and 
are exposed to strong selection. This means "first causes" cannot be 
precisely defined. Nevertheless the clear possibility that 
immunoglobulin somatic hypermutation may be one of these "first 
causes" promoting somatic mutation, both across the genome and in 
key gene regulators such as TP53, is worth pursuing in its own right 
as the implications have wide and interesting ramifications for the 
future directions of cancer research.  
 
 
Somatic Hypermutation in rearranged Ig Genes : The 
mechanism of SHM of Ig VDJ  genes is now well understood and 
many molecular steps are known or can be plausibly inferred [3-5]. 
More recently this knowledge has been applied to the etiology of 
cancer. What we discovered in a preliminary analysis was that the   7 
characteristic strand-biased mutation signatures of Ig SHM were 
present, in toto or in part, in a number of somatic mutation datasets 
posted at the Welcome Trust Sanger Institute's website run by the 
institute's Cancer Genome Project [6]. Indeed the possibility has 
often been discussed that dysregulation of SHM driven by activation 
induced cytidine deaminase (AID) conversion of cytosine to uracil (C-
to-U) in DNA - normally confined to antigen-stimulated B 
lymphocytes in post-antigenic Germinal Centers - could lead to 
somatic mutations and translocations in non-Ig genes thus 
contributing to oncogenesis [7-10]. 
  The aim here is to use these insights from the Ig SHM field to 
help explain the strand-biased mutation signatures in TP53 in human 
non-lymphoid tumors arising by as yet unknown "endogenous" 
mechanisms. We have analysed in detail strand-biased TP53 
mutation signatures in breast, bladder and lung cancers. These are 
exemplars of oncogenesis in tissues exposed directly to carcinogens 
in tobacco smoke (lung) or indirectly exposed to such carcinogenic 
metabolites (bladder via urine) versus cancers arising in tissues such 
as breast generally considered "as least accessible to tobacco smoke" 
and other known exogenous agents [1,2,11].  
  We have also analysed and compared strand-biased mutation 
signatures and mutation patterns in other cancerous tissues. The 
analytical reviews by Soussi [1] and Pfeifer and Besaratinia  [11]   8 
have proved valuable and we recommend these papers and related 
literature be read in association with the present analysis. 
 
Strand-Biased Mutation Signatures in Ig Genes : Strand biased 
mutation signatures in Ig VDJ gene loci, particularly at A:T base 
pairs, have been recognised for over 25 years [12]. More recently  
published data (1984-2008) on mutated mouse VDJ regions and their 
3' JH4-flanks have been analysed [5]. In this study, somatic mutation 
data from thirty two independent studies are summarised and are 
available in a meta-analysis in the Supplementary Data. Little 
significant new data has been published in the SHM field since then 
that changes the basic patterns shown in Table 1 or their 
interpretation.  
  The essence of this analysis established that the Ig SHM 
mutation pattern free of "PCR recombinant artefacts" reveals several 
significant strand-biased mutation signatures at A:T and G:C base 
pairs (Table 1A). The first is at A:T base pairs where mutations of A 
exceed mutations of T by almost three fold, particularly the dominant 
strand bias of A-to-G exceeding T-to-C mutations. The second main 
strand bias is at G:C base pairs where mutations of G exceed 
mutations of C by at least 1.7 fold. The dominant strand bias here 
concerns G-to-A exceeding C-to-T mutations.   9 
  The distortion in the DNA sequence data contaminated with 
PCR-recombinant artefacts (Table 1B) has previously masked the 
clear strand bias at G:C base pairs. This distortion has also made it 
difficult for the field to develop their understanding of the mutator 
mechanisms operative on A:T and G:C base pairs during Ig SHM in 
vivo [5,13]. 
  The significant presence of PCR-recombinants - also referred to 
as PCR-hybrids or mosaic heteroduplexes at the end of a PCR run is 
due to Taq or Pfu polymerase denaturation generating incomplete 
extension products acting as forward and reverse primers during 
amplification cycles.  They arise from PCR runs where amplification is 
from multiple similar templates using the same set of primers. For 
this reason, the inevitable presence of such sequence artefacts 
causes blunting if not complete ablation of strand-biased mutation 
signatures following cloning in E.coli and then sequencing of PCR 
inserts. Such problems are avoided by reducing PCR cycle numbers, 
by sequencing target VDJ genes expressed in hybridoma clones or 
direct sequencing of amplification products from single VDJ loci 
expressed in FACS sorted single B lymphocytes [5,13-15]. 
  As a consequence of these analyses the reference strand-biased 
Ig SHM mutation pattern we will use as a comparator for the TP53 
mutation data is shown in Table 1A. The patterns in Table 1A are 
essentially free of strand-biased blunting PCR hybrid artefacts.    10 
  For comparison, Table 1B shows the previously cited pattern in 
the SHM field where there is no strand-bias evident at G:C base 
pairs. Note that in Table 1A the magnitude of the ratio of mutations 
of A versus mutations of T (hereafter indicated as the A>>T ratio) is 
reduced from 2.8x to 1.9x in Table 1B. Thus there is significant 
blunting of the established A>>T mutation ratio (as well as the 
dominant and diagnostic A-to-G versus T-to-C ratio, below) and 
compete ablation of the lower (1.7x) yet significant G>>C strand 
biased ratio (compare Tables 1A and 1B).  
  In summary, we now know that the SHM reference pattern 
shown in Table 1A is characterised by significant strand biases 
evident for all Watson-Crick complements: A-to-T v T-to-A; A-to-C v 
T-to-G; A-to-G v T-to-C and G-to-A v C-to-T; G-to-T v C-to-A; G-to-C 
v C-to-G.  
  We first addressed this issue [13] by making the point that "the 
synthesis of a mutated cDNA copy of the transcribed strand (TS) off 
the pre-mRNA template, and replacement of the original TS with the 
cDNA is inevitably strand-biased (see Fig 1)."   This was underpinned 
by the finding that the error-prone Y family DNA polymerase-eta (!), 
an enzyme shown to be at least involved in translesion DNA repair, 
reviewed in Goodman [16], was an efficient reverse transcriptase at 
low enzyme-to-RNA template ratios in vitro [17]. It is now firmly   11 
established that Pol-! is the only DNA polymerase involved in 
physiological Ig SHM in vivo [18,19].  
  The SHM field now accepts that Pol-! mutates A:T base pairs, 
particularly A-sites at certain WA hotspots where the target A is 
preceded 5' by A or T (=W). With the analysis of most published 
experimental data 1984-2008 (see legend Table 1) a unifying 
explanation can be provided for the central role of base-modified RNA 
template intermediates and cellular reverse transcription in the 
generation of all the Watson-Crick strand biases displayed in Table 
1A. 
   In the updated version of the reverse transcriptase model (RT 
model SHM, initially proposed in Steele and Pollard [21]) the two 
different sets of mutation strand biases at A:T and G:C base pairs 
can, we believe, be explained by a common core mechanism (Figure 
1) : emergence of an error-filled mRNA intermediate followed by 
reverse transcription via DNA polymerase-! [5]. In the case of the 
A>>T strand bias the model proposes a combination of adenosine to 
inosine (A-to-I) pre-mRNA editing by ADAR1 deaminase [24] and A-
to-T and A-to-C biases via the RT activity of Pol-! during the cDNA 
synthesis step. In the case of G>>C strand bias it proposes that RNA 
mutations (G-to-A, G-to-C) generated by RNA Polymerase II 
(RNAPII), transcribing a DNA template (TS) carrying AID-lesions 
(uracils and abasic sites), followed then by the RT activity of Pol-!.   12 
This can be considered a form of "transcriptional mutagenesis" as 
proposed in Fig 3b in Hanawalt and Spivak [25] but coupled now to 
DNA fixation by reverse transcription. 
  According to the RT-model, for the G>>C mutation signatures 
the G-to-A v C-to-T strand bias results from rA being incorporated 
into RNA opposite unrepaired dU on the TS and the G-to-C v C-to-G 
strand bias results from rC being incorporated into RNA opposite an 
abasic site on the TS [23]. For the G-to-T v C-to-A strand bias this 
would be the alternative pyrimidine substitution (rU) if rC is not 
inserted opposite an abasic site (Note : modified G residues in DNA 
due to reactive oxygen species such as 8oxoG are not known to play 
a role in physiological SHM in vivo [20] and below). 
  Recently, we have applied this updated RT-model for DNA 
diversification to both the etiology of strand-biased mutation patterns 
in many non-lymphoid cancers [6] and, amongst other hypotheses, 
to the origin of the established genome-wide strand bias for A-to-G 
over T-to-C in transcribed regions of the human genome [26]. The 
RNA modifications we are considering are non-bulky simple changes 
to base pairing, such as adenosine-to-inosine deamination in RNA 
[24] or putative 8oxoG modifications at G residues in RNA [6]. For Ig 
SHM and in our genome-wide diversification analysis, we have 
strongly argued against conventional explanations of strand-biases 
(mainly the A-to-G v T-to-C bias) for repair of non-bulky DNA lesions   13 
caused by differential DNA repair of transcribed (TS) as opposed to 
non-transcribed (NTS) strands during transcription-coupled repair 
(TCR). Indeed, critical evaluation of the TCR field has so far not 
provided evidence to support a TCR-mediated mechanism for strand 
biases arising from non-bulky DNA lesions such as C-to-U and abasic 
sites [26]. Further, in the case of the repair of 8oxoG lesions in DNA 
the Bohr group have convincingly shown that there is no 
transcriptional strand bias in their repair [27]. 
 
Origin of the A-to-G versus T-to-C Strand Bias: The A-to-G 
versus T-to-C strand bias is a common strand bias in many somatic 
and germline mutation data sets. This strand bias is found not only in 
all SHM data sets in mouse and human VDJ genes, in families of 
similar human germline IgV segments (in Matsuda et al [28], EJS 
unpublished analysis) but also in almost all TP53 cancer data sets 
where A/T mutations have not been significantly suppressed or 
ablated (presumably by genetic deficiencies affecting the mismatch 
repair (MMR) machinery as in colorectal, stomach, oesophagus 
adenocarcinomas, skin, rectum and colon cancers, below). And in all 
cases examined, A-to-G mutations are enriched at some but not all 
A-site hotspots where the A target is preceded by a 5' A or T (=W). 
  Key evidence supporting an RNA template intermediate model 
for the prominent A-to-G versus T-to-C mutation strand bias derives   14 
from an IgV mRNA-stem loop computational analysis where the RNA 
substrate for ADAR1 mediated A-to-I deamination was modelled and 
tested on the  somatic mutation data set of the rearranged light chain 
encoding V"Ox1 passenger transgene [24].  Thus, in an RNA-based 
pathway for immunoglobulin SHM, A-to-I RNA editing causes A-to-G 
transitions since I like G pairs with C. The adenosine deaminases 
(ADARs) are known to preferentially edit A sites that are preceded by 
an A or U (W) in double-stranded RNA substrates [29]). We showed 
that a significant and specific Pearson correlation (P<0.002) exists 
between the frequency of WA-to-WG mutations and the number of 
mRNA hairpins that could potentially form at the mutation site. 
Indeed the statistical significance of the correlation improved with 
increased stem length (or stability) of the dsRNA substrate (Fig 11, in 
ref. [24]) and proximity of the nascent dsRNA to the transcription 
bubble. It is known that ADAR1 edits pre-mRNAs in the nucleus prior 
to splicing [30,31]. Indeed ADAR1 seems to act on the WA-site 
closest to the transcription bubble and explains why the A-stem 
partner in the target A:U editing site must be previously synthesised 
[24]. This study strongly implies a role for both RNA editing and 
reverse transcription during SHM in vivo involving ADAR1 and Pol-
!  acting in its RT mode. For these reasons, we consider the elevated 
A-to-G v T-to-C ratio as a diagnostic for mutational strand bias   15 
caused by modified RNA template intermediates and DNA fixation via 
reverse transcription. 
  However key direct experimental evidence supporting an RNA 
template intermediate model is still lacking. The ideal experiment in 
the context of Ig SHM would be a conditional genetics approach 
targeting ADAR1 expression in mature B lymphocytes in antigen-
activated Germinal Centers. In a collaboration Cre-lox specific gene 
targeting techniques were used to inactivate ADAR1 during SHM in 
vivo. A positive result might involve a clear reduction or complete 
removal of the A-to-G component of the SHM mutation spectrum 
(that is, those A-to-G changes which correlate strongly with WA sites 
in dsRNA stem loops). If however ADAR1 is a more central player in 
the SHM process it may also result in a total reduction in mutations at 
A:T base pairs (leaving intact mutations at G:C base pairs). In the  
recent collaboration ADAR1flox alleles on the C57BL6 mouse 
background, Wang et al 2004 [32]) were crossed into C57BL6 mice 
with  a ‘knocked-in’ Ig antigen receptor (the SWHEL IgVH10 single-
copy heavy chain transgene) which was assayed for somatic 
hypermutation in the adoptive transfer system described in Paus et al 
2006 [33]. An inducible Cre-recombinase gene when activated by 
tamoxifen should specifically target the ADAR1floxed alleles and 
delete them from B lymphocytes activated by antigen into the 
somatic hypermutation pathway. Unfortunately no mature donor B   16 
lymphocytes could be recovered in Germinal Centers suggesting that 
one or more ADAR1 sensitive developmental steps were necessary 
leading to Germinal Center B lymphocytes. Therefore with current 
Cre-lox technology approaches to implementing a successful 
experiment targeting ADAR1 alleles seem limited (R. Brink, K. 
Nishikura, G. F. Weiller, E. J. Steele unpublished data 2007-2009 ).  
  With respect to carcinogenesis, unregulated ADAR-mediated A-
to-I RNA editing is a well described phenomenon [34,35]. In a similar 
vein, unregulated APOBEC family C-to-U DNA deaminases such as 
AID, APOBEC3G and APOBEC1 are comparable rogue mutator 
processes thought to be operative in many cancers [7-10]. Thus for 
the present analysis we can reasonably assume that unregulated RNA 
and DNA deamination processes (at rA and dC residues) may well be 
associated with either the genesis or progression of many non-
lymphoid cancers. Here we are concerned with the molecular 
implications of such processes particularly in relation to 
understanding the strand-biased mutation signatures at A:T and G:C 
base pairs in the TP53 gene and wider genome. 
 
 
THE TP53 MUTATION DATABASE 
 
The DNA sequence encoding the human tumor suppressor protein 
TP53, on chromosome 17 located at 17p13.1, has been cloned and   17 
sequenced as both full length DNA and cDNA in many tumors over 
the past two decades. Mutated variants of the TP53 germline 
sequence carrying somatic mutations mainly in the region encoding 
DNA binding, are found in a wide range of cancers [1,11,36]. 
Oncogenic TP53 mutations are a biased dataset in that they are 
partially selected for a competitive binding function focused on the 
DNA binding region. They are usually missense mutations in one 
allele spanning many sites in the TP53 coding DNA from about codon 
130 to 300 [1]. Many investigators have deposited their sequence 
data in the database funded by the WHO at Lyon in France. The 
WHO-IARC public database has now curated around 30,000 somatic 
mutations in TP53. The data analysed here was extracted from this 
source [37] (http://www-p53.iarc.fr/, R15, November 2010). 
 
Method of Data Extraction and Presentation : The somatic point 
mutation data presented in the Tables were extracted from the 
database as  follows. On entering the website (http://www-
p53.iarc.fr/) "Database Search" is selected allowing entry to 
http://www-p53.iarc.fr/p53main.html which allows selection of 
"Search database for data related to SOMATIC MUTATIONS" and 
selection of "Search (Tumor types)". This allows entry to http://www-
p53.iarc.fr/BasicCriteria.asp where the tumor site can be selected at    
" Select a tumor site"  and thus entry to "Mutation pattern"  ( at   18 
http://www-p53.iarc.fr/Graph.asp ) where selection can be made for 
the key data sets : "Strand distribution"  and "Download data". The  
"Strand distribution" tables can be downloaded where numbers of all 
12 possible base substitutions are displayed including the numbers of  
C-to-T and G-to-A mutations at CpG islands. The spreadsheet from 
"Download data" allows construction and analysis of all types of 
mutations with 5' and 3' flanking sequence context in relation to the 
unmutated TP53 exon sequence (and in some cases intronic 
sequence). This allows development of frequency distributions of 
various types of mutation (e.g. A-to-G) versus nucleotide (and 
codon) position across regions of interest such as the DNA binding 
region eg Figure 2.  
 
Statistics : Displayed in each base substitution table are Chi-squared 
statistical comparisons (1 df) of several types of base substitutions. 
Thus for A:T base pairs the main comparisons are all mutations of A 
versus all mutations of T - when strand biased for excessive 
mutations of A this is symbolized as "A>>T".  The common and 
dominant A-to-G strand bias is represented as  " A>G v T>C". Other 
types of biases are presented and tested similarly. Thus when 
mutations of G exceed mutations of C this is symbolized as " G>>C"; 
when G-to-A mutations exceed C-to-T mutations this is symbolized as   19 
" G>A v C>T". The Appendix explains the rationale for detecting 
strand biases in mutation datasets. 
    
TP53 STRAND-BIASED MUTATION DATA 
 
The strand-biased mutation pattern typical of normal Ig SHM (Table 
1A) was compared with the somatic point mutation patterns observed 
in the TP53 coding region for a range of key cancers (Table 2).  Chi-
squared tests were applied to test the levels of statistical significance 
of the various strand biases. Attention was focused on mutations of A 
and G respectively, particularly A-to-G versus T-to-C, G-to-A versus 
C-to-T and G-to-T versus C-to-A as the analysis of these strand-
biases has implications for the molecular mechanisms involved.    
  The main strand-biased mutation patterns observed in TP53 are 
best represented by the patterns in All Breast, All Bladder and All 
Lung cancer categories - where each has many (>1000) somatic 
mutations to analyse (Table 2).  We have ranked these tissues in 
their likely exposure to carcinogens in tobacco smoke as smoking is 
the leading cause of lung and many other cancers in the world today. 
The origin of TP53 mutations in breast may be considered the least 
likely to be caused by direct exposure to tobacco smoke carcinogens 
and metabolic by-products [2].   20 
   In the case of TP53 mutations in bladder cancer we assume 
the tissues are at least exposed to relatively high levels of 
carcinogenic metabolic by-products of tobacco smoke in urine.  
  In the case of TP53 mutations in lung cancer there is direct 
tissue exposure to tobacco smoke polycyclic hydrocarbons (PAHs) 
and carcinogenic metabolic derivatives [38]. Here the molecular, 
biochemical and cellular evidence is overwhelming. Exposure to such 
smoke-derived carcinogens causes lung cancer. In particular, bulky 
DNA adducts at certain G sites targeted by carcinogens such as 
benzo[a]pyrene (B[a]P) is the direct cause of the dominant G-to-T 
transversion in these cancers in the TP53 gene [39-41] (reviewed in 
[1,11] ) and throughout the wider lung cancer genome [42]. 
  Some striking similarities are observed for the cancers shown in 
Table 2.  
  a. The first is the similarity between the Ig mutation pattern 
(Table 1A), and the patterns in TP53 for "All Breast " and "All 
Bladder" cancers. The main difference between the Ig pattern and the 
TP53 pattern in breast and bladder (and with many other TP53 cancer 
data sets for that matter) is the ~ 50:50 balance of mutations at A/T 
and G/C for Ig versus the G/C excess over A/T in TP53. The majority 
(70-75%) of TP53 mutations occur at G/C sites. This may be partly 
contributed by the significant excess of G/C (~ 60%) versus A/T 
(~40%) base composition of the target region in TP53.  But the   21 
pattern similarities nevertheless exist within A:T base pairs and G:C 
base pairs.  
  b. The second systematic pattern observed in all data sets 
shown in Table 2 is the A>>T and A-to-G versus T-to-C strand bias. 
They stand out as common strand-biased patterns. To our knowledge 
of the mainstream TP53 literature this strand bias is rarely 
highlighted in published discussions. However, this pattern is not 
observed in colorectal, stomach, skin, and some other cancers as A/T 
mutations here have been ablated or significantly reduced (below). 
This pattern is stable across breast, through bladder to lung (and all 
ovary cancers, Table 3) suggesting a common causal mechanism that 
may not be associated with exposure to carcinogens in tobacco 
smoke. For A-to-G hotspots in both breast and lung cancers, the 
majority are defined by being part of a WA-site, particularly at codons 
132, 163, 205, 220, 234, 239; the TAT site in codon 220 is a super 
hot spot (data not shown). 
  If the A-to-G spectrum in TP53 at all A-sites in codons 100-300 
inclusive for "All Breast Cancer" is compared with the same spectrum 
in "All Lung Cancer", they are virtually super imposable (Figure 2) . 
The Pearson correlation coefficient (r) is 0.93, which for 129 degrees 
of freedom gives a P<0.001.  Indeed, we think that this repeatable 
pattern in the two disparate target tissues is consistent with their 
origin being the result of an "endogenous" process. By comparison   22 
with what we have inferred from Ig SHM (Figure 1) a likely candidate 
is unregulated ADAR1-mediated A-to-I RNA editing and fixing of the 
mutated retro-transcripts back into DNA via reverse transcription as 
envisaged for Ig somatic hypermutation. The cellular reverse 
transcriptase could be DNA polymerase-! (or one of it's Y family 
relatives iota (#) and kappa (")) which also possess significant reverse 
transcriptase activity, [17]).  
  c. The third common pattern is the excess of G mutations over 
C mutations (G>>C), particularly the dominant G-to-A over C-to-T 
strand bias (evident at both CpG and non-CpG sites). The pattern in 
breast and bladder is very similar again, suggesting common causal 
mechanisms. All ovary cancers display a similar pattern (Table 3). 
Again, to our knowledge of the mainstream TP53 literature, this 
particular and striking strand bias is rarely highlighted in published 
discussions on the topic. 
  The likely cause of the G>>C imbalance for lung cancer is 
known to be due to the binding of bulky tobacco smoke-derived 
adducts such as B[a]P at certain G-sites  (mainly CpG islands 
although GpG sites can be targeted) in known critical codons such as 
154, 157, 158, 245, 248, 249, 273.  Such adducted G-sites now 
mispair with adenosines causing G-to-T transversion mutations if left 
unrepaired. This grossly imbalances other G mutations at these sites   23 
leading to a loss of the G-to-A v C-to-T strand bias evident in breast, 
bladder and ovary cancers. 
  Direct experiments by Pfeiffer and colleagues have shown that 
the G-to-T v C-to-A strand bias is caused by the much slower repair 
of bulky DNA adducts such as B[a]P along the nontranscribed strand 
compared with the faster repair on the transcribed strand [41].  So 
the strand biased G-to-T pattern is a direct consequence of a 
transcription-coupled DNA repair (TCR) process for bulky DNA 
adducts [25].  This is a DNA-based strand-biased mutation 
mechanism and thus quite different from the RNA-based mechanisms 
outlined above for Ig SHM (Figure 1).  
  Before leaving this section we wish to deal with two further 
issues. First, we must deal with a relevant point that has now 
emerged from whole genome sequencing of individual lung cancers 
such as NCS-H209, Pleasance et al [42]. In a critical section on the 
origin of the DNA repair pathways that may be responsible for the 
complex strand biased signatures of tobacco exposure the authors 
make the following set of statements and assumptions : 
    "… that bulky adducts on purines are the predominant form of 
  DNA damage induced by tobacco carcinogens and can be 
  sufficiently disruptive  to impede RNA polymerase when they 
  occur on the transcribed strand.. " and they observed " that 
  guanine and adenine substitutions are generally less frequent   24 
  on the transcribed than the non-transcribed strand - confirming 
  that purines seem to be the major target of carcinogens in 
  tobacco smoke."   
  We accept this explanation for the origin of the G-to-T 
transversions but our data do not support their conclusions on the 
origin of the A-to-G strand bias.  Indeed we would hardly expect the 
A-to-G spectra in TP53 to be identical in lung and breast cancers 
(Figure 2) if this is the case. The fitted curves in Pleasance et al [42] 
show the effect of gene expression on strand bias mutation rate for 
the six classes of adenine and guanine mutations in NCI-H209 (Fig2e 
in [42]). The overall patterns are to be expected from the TP53 lung 
cancer pattern (Table 2C) which the authors acknowledge in their 
Supplementary data. However the profiles for G-to-T and A-to-G are 
quite different. The decline in G-to-T mutation rate with increased 
transcription level is biphasic suggesting two causal DNA repair 
mechanisms for G-to-T: one to be expected and rapid depending on 
increased transcription involving TCR of bulky adducts, the other 
suggestive of another strand bias process. This could be due to 
perhaps 8oxoG generation by reactive oxygen species in RNA and an 
RT step of RNA->DNA fixation.  
  The curve for A-to-G mutation rate versus transcription level 
appears monophasic with the difference between the repair of the 
NTS and TS mutations deepening with increased gene expression (or   25 
transcription). However the slope of the curve is very shallow - a 
slight decline in mutation rate from expression level 4 to 9 ( ~2.9 
mutation rate/Mb to ~ 2.5 mutation rate /Mb). This suggests a 
constitutive process of error generation and repair marginally affected 
by transcription level. One interpretation could be that this is 
consistent with A-to-I RNA editing, and RNA->DNA fixation. 
  The second issue adds to the argument against asymmetrical or 
strand-differential TCR as an explanation for the excess of G-to-A 
mutations over C-to-T mutations in both Ig SHM and somatic 
mutation patterns in TP53 in cancers such as in breast. If TCR was 
occurring to clear C-to-U lesions arising from the action of 
unregulated APOBEC family deaminases in cancer cells (or 
progenitors) we would expect a preferential clearance of C-to-U on 
the TS and an excess of unrepaired C-to-U lesions, manifest as C-to-
T, on the NTS. In fact in Ig SHM and in mutated TP53 genes in breast 
and other cancers (Table 2) it is the other way around. An excess of 
G-to-A over C-to-T suggests that C-to-U lesions would need to go 
unrepaired preferentially on the TS which is not evident in the 
mutation patterns analysed here. 
  So the argument goes full circle posing the question why then 
should G-to-A mutations exceed C-to-T mutations? This conundrum 
may explain why the G-to-A >> C-to-T strand bias has gone 
relatively unreported in the literature.  The simplest explanation of   26 
the G-to-A strand bias is that C-to-U goes unrepaired on the TS prior 
to RNA Pol II copying this into G-to-A in the mRNA  [23] which in turn 
would be manifest in a strand-biased manner in the DNA by reverse 
transcription first as a C-to-T in TS DNA and then following replication 
as G-to-A on the NTS [5] ( and see Figure 1). This is the simplest 
explanation of the G-to-A versus C-to-T strand bias involving 
AID/APOBEC3G/APOBEC1-deaminations in DNA. The same argument 
for G-to-C over C-to-G in SHM and TP53 mutation patterns in breast 
and other cancers with similar mutation patterns (eg bladder Table 
2B) is used, and the lesser strand bias of G-to-T over C-to-A. In the 
TP53 mutation pattern in breast cancers the relative increase in the 
G-to-T over C-to-A ratio compared to that in Ig SHM (Table 1A) - in  
"a tissue less exposed to smoke" - suggests it might be contributed 
by another mechanism. One possibility is the formation of 8oxoG in 
the TP53 mRNA (as suggested in Steele and Lindley [6]) because it is 
known that 8oxoG DNA lesions are unlikely to display strand 
differential TCR biases on DNA repair [27]. Further research on the 
genetic and biochemical consequences of 8oxoG formation in RNA is 
clearly required.  
 
TP53 G->T VERSUS C->A STRAND BIASES IN OTHER CANCERS 
   27 
B[a]P and similar DNA-binding tobacco-derived carcinogens are 
known to form bulky G-site adducts causing G to base pair like T with 
adenosines. These bulky adducts are preferentially cleared from the 
transcribed strand during transcription-couple repair and this causes 
the excess of G-to-T mutations on the upper non-transcribed strand. 
In a similar vein, in hepatocellular liver cancer the G-to-T versus C-
to-A strand bias is caused by adduct formation at G-sites by aflatoxin 
dietary contaminants, diagnostically at the third position of codon 249 
in TP53 [36]. This G-site (GpG) is also a G-to-T hotspot in many lung 
cancers.  
  Other geographically and ethnically localised strand biases via 
dietary contamination for G-to-T over C-to-A , and for A-to-T over T-
to-A are reviewed in [1,36]. Thus G-to-T transversions in the third 
base of TP53 codon 249 correlates strongly in tumors from HBV 
carriers and exposure to dietary aflatoxinB1; and A-to-T strand bias  
(codons 131,209,280)  has been linked with crops contaminated with 
Aristolochia sp seeds ( in certain Balkan communities in southeastern 
Europe). Aristolochic acids (AA) is the identified carcinogenic agent, 
and DNA adducts involving AA have been detected in patients 
suffering from Balkan endemic nephopathy (BEN). The strand bias 
suggests preferential TCR of bulky DNA lesions along the transcribed 
DNA strand as concluded already for G-to-T strand biases in many 
lung cancers.   28 
DNA REPAIR DEFICIENCIES : COLORECTAL, STOMACH AND 
SKIN CANCERS 
 
There are also some other more complex TP53 mutation patterns not 
conforming to the simple strand biases just discussed and worthy of 
further comment here. Before we do this, it is informative to consider 
what is known about DNA repair deficiencies and distortions of the Ig 
SHM mutation pattern (Table 1 and Table 4). Much of this work has 
been done using single and double knockout mice targeting key base 
excision repair (BER) and mismatch repair (MMR) genes encoding 
proteins that have been co-opted to now function aberrantly (a form 
of "subverted DNA repair" as put by Martomo and Gearhart [52]), see 
summary in Table 4 and review in Steele [5]. The various protein 
components of the normally tightly regulated and targeted Ig mutator 
now act to encourage error-prone DNA synthesis during the somatic 
hypermutation of rearranged antibody variable genes in Germinal 
Center B lymphocytes following antigenic challenge. The key proteins 
and DNA repair enzymes are AID deaminase which initiates the SHM 
process (and Ig class switch recombination, CSR) by deaminating C- 
to-U in VDJ DNA; this is then followed by attempts to remove the 
base in a base excision repair (BER) manner via uracil DNA 
glycosylase (UNG), followed by other "subverted" DNA repair   29 
enzymes such as translesion DNA polymerase !, and the mismatch 
repair heterodimer MSH2-MSH6. 
  Table 4 lists the main consequences on the Ig SHM mutation 
spectrum of genetic deficiency in uracil DNA-glycosylase (UNG), in 
the mismatch repair heterodimer (MSH2-MSH6), and deficiencies in Y 
family DNA polymerases ! (eta), i (iota) and " (kappa) and 
combinations thereof. Additional deficiencies are shown : in 
alkyladenine DNA glycosylase (Aag) which removes hypoxanthine 
(deaminated adenine) from DNA generating an abasic site and 8-
hydroxyguanine-DNA glycosylase (Ogg1) which removes oxidised 
guanine from DNA. The affect on the SHM spectrum of inactivating 
TP53 is also shown. 
  In Ig SHM a failure to remove uracils from DNA as a 
consequence of dC-to-dU AID deaminase action (UNG-/-, Table 4) 
has a slight affect on overall A/T mutations and no effect on A>>T or 
A-to-G strand biases. The main effect is on the focusing of mutations 
to G:C base pairs with a reduction in transversion mutations.  
  In UNG-/-MSH-/- double deficient mice mutations at A:T base 
pairs are virtually eliminated as are transversions at G:C base pairs 
leaving what is considered the "AID deamination footprint" (Table 4, 
[44]) which now manifests itself as a strong strand bias of C-to-T 
exceeding G-to-A by at least 1.5 fold [5]. The simplest interpretation 
is that since AID-deaminase converts C-to-U in the single stranded   30 
DNA regions of the transcription bubble, this is likely to happen more 
often on the NTS than the TS, thus the unfettered C-to-T over G-to-A 
strand bias in such mutant mice. The same strand bias is revealed in 
double deficient Pol!-/-/MSH2-/- mice [18]. These data are 
consistent with SHM models whereby MSH2-MSH6 heterodimers 
engage G:U DNA mispairs and recruit Pol ! necessary for full blown 
mutagenesis at A:T base pairs [53]. In the complete absence of Pol 
!, Pol-" can step in to affect A/T mutagenesis [19] and probably also 
the RT step [17].  
  With respect to the general over-arching molecular mechanism 
of Ig SHM the deficiencies in Aag, Ogg1 and TP53 are informative. 
First, the failure to remove 8oxoG from DNA has no affect on the Ig 
SHM spectrum [20] indicating that the G-to-T/C-to-A component of 
the SHM  spectrum does not involve 8oxoG residues in DNA. This 
leaves open the possibility that 8oxoG sites in RNA may contribute in 
other somatic mutation scenarios such as in TP53 as envisaged in 
Figure 1. Second, direct deamination of adenines in DNA to 
hypoxanthine (and thus potential A-to-G miscoding) seems to play no 
role in the generation of the A-to-G spectrum [48] once again leaving 
open the possibility of adenosine deamination to inosine at the RNA 
level contributing significantly to the observed A-to-G strand bias as 
envisaged in Figure 1. The investigators also observed a borderline 
statistically significant (P~0.03) increase in T-to-C in Aag (-/-) mice -   31 
in our view this variation in T-to-C frequency is well within the range 
of variation for these PCR based SHM assays as outlined in Steele [5] 
and supplementary data therein. Third, and most importantly for the 
present analysis, Storb and associates have clearly shown an affect of 
TP53 inactivation on the Ig SHM spectrum - there is a striking 
increase in A-to-G frequency in such mice and a corresponding 
increase in both A-to-G versus T-to-C and A>>T strand bias [49]. 
This result suggests that TP53 inactivation can profoundly affect the 
A-to-G component of the SHM spectrum thus implies that the global 
DNA damage surveillance function of TP53 extends, as expected [49] 
, to Ig SHM. In the context of the present analysis the result suggests 
that TP53 may well regulate the imprint of A-to-I RNA editing on the 
DNA somatic mutation pattern as predicted by the RT model of Ig 
SHM (Figure 1). This in turn has implications for the magnitude of the 
A>>T and A-to-G versus T-to-C strand biases across the human 
cancers bearing inactivated TP53 alleles such as for example, bladder 
(Table 2B ) and ovary cancers (Table 3) and the wider cancer 
genome.   
  With respect to the other major affects on A/T and G/C 
mutations can we find parallel, or similar, patterns in other cancers 
with TP53 somatic mutation data? It is well known that colorectal and 
other aggressive gastrointestinal cancers are typified by the known 
high incidence of defects in mismatch DNA repair machinery, Bellizzi   32 
and Frankel 2009 [54]. We would therefore expect, if subverted DNA 
repair components of the Ig SHM process are operative in such 
tumors, that the signature of ablated or suppressed A/T mutagenesis 
should be revealed in the TP53 patterns in such cancers. This 
expectation is partly satisfied by the TP53 mutation data on colorectal 
and stomach cancers (Table 5) where A/T mutations have been 
reduced (but not eliminated) in colorectal and stomach cancers. In 
some cases the A-to-G strand bias has been retained (stomach Table 
5B) and in other cases it is lost (colorectal cancers, Table 5A). 
Reductions in A/T mutations are also noted in eosophagus 
adenocarcinomas (not shown). Whilst there is a relative excess of G-
to-A and C-to-T mutations at presumed methylated CpG sites in 
colorectal cancers, the strand bias here is also evident at non-CpG 
sites (not shown). In contrast, the TP53 mutation patterns in 
stomach cancers lack significant strand biases apart from those 
involving A-to-G v T-to-C and G-to-T v C-to-A (Table 5B). It is 
conceivable that unrepaired excessive C-to-U deaminations on the 
NTS (relative to TS) are blunting intrinsic strand biases of G-to-A v C-
to-T in the same way such blunting (or strand bias reversal) occurs in 
Ig SHM in UNG-/-MSH-/- and Pol !-/-/MSH-/- mice (Table 4, and see 
extended discussion on this point in Steele [5]). 
  TP53 mutation patterns in skin cancers are shown in Table 5C. 
Here there is both suppression of A/T mutagenesis and a reversal of   33 
the strand bias at G/C sites, namely, C-to-T mutations clearly exceed 
G-to-A mutations by almost 2 fold. This is similar to data for Ig SHM 
in mice displaying the "AID deamination footprint" in UNG-/-MSH-/- 
and Pol !-/-/MSH-/- mice (Table 4, [18,44]). 
  In summary, known DNA repair deficiencies in previously 
characterised Ig SHM model systems are displayed in toto or in part 
in TP53-bearing cancer mutation patterns. The results are consistent 
with the hypothesis that components of "subverted DNA repair" play 
a similar role in both SHM and non-lymphoid cancers bearing mutated 
TP53 derivatives. In addition inactivation of TP53 may increase the 
magnitude of A>>T and A-to-G versus T-to-C strand biases in the 
tumors that harbor mutated TP53 derivatives [49].   
 
TP53 MUTATION PATTERNS IN BRAIN CANCERS 
 
This particular pattern is discussed at length in Soussi [1] and 
displayed in Table 6. Note that a trend to A>>T strand bias, and a 
significant A-to-G v T-to-C strand bias is evident. There is also a 
specific strand bias of G-to-T transversions over C-to-A. However the 
global G>>C strand bias has been ablated, particularly the 
dominance of mutations of G-to-A v C-to-T evident in many other 
cancers harboring mutated TP53 variants. As Soussi [1] discusses, 
there are similar numbers of excessive G-to-A and C-to-T mutations   34 
at CpG sites suggesting excessive deaminations of 5-Methylcytosine-
to-T on both DNA strands (Table 6). The latter may be affected by 
AID-deaminase [9]. Once again however, as with the analysis of 
mutation patterns in Ig SHM, competing strand-biased mutational 
processes at G:C base pairs may accentuate, blunt, ablate or even 
reverse the strand biased signature presented by a particular tumor. 
 
 
CONTEXT OF C-TO-U LESIONS BY APOBEC-FAMILY 
ENZYMES   
 
This topic has been extensively studied by the Neuberger group [8]. 
Here we summarise the main findings and relate them to the 
sequence context of TP53 mutations in lung and breast cancer. For 
mutations off G most if not all occur at one of the known 5'NCN3' 
motifs on the opposite deamination strand. Thus APOBEC1 targets 5'-
TCA-3' on the deamination strand (or 5'-TGA-3' on the NTS) ; 
APOBEC3G targets 5'-CCG-3' (or 5'-CGG-3 on the NTS) and AID 
variously targets in descending order 5'-ACA-3', 5'-GCA-3', 5'-ACG-3' 
and 5'-GCG-3' (or 5'-TGT-3', 5'-TGC-3', 5'-CGT-3' and 5'-CGC-3' on 
the NTS). We also include the possibility that 5-MeC-to-T 
deaminations are affected by such enzymes [9].   35 
  When this information is applied to the G-site mutations of the  
"endogenous pattern" represented by the All Breast Cancer data it 
reveals that all major and minor G-site mutation hot spots can be 
classed as the direct result of either AID or APOBEC3G C-to-U 
deaminations targeting the transcribed TP53 DNA strand (Table 7). 
The dominant likely C-to-U deaminase is AID suggesting that 
dysregulated SHM initiation via AID activation in non-lymphoid tissue 
may be the primary cause of the mutagenesis leading to cancer.    
 
BREAST CANCER MUTATION PATTERNS IN TP53 
COMPARED WITH PATTERNS IN GENOME-WIDE DATA   
 
The somatic mutation patterns in TP53 is often a very good correlate 
to genome-wide point mutation patterns eg. lung cancer [42]. 
However this is not always the case probably because TP53 is not 
inactivated in all cancers of a given category e.g. about 25% of 
breast and bladder cancers, 48% of ovary cancers and 38% of lung 
cancers have an inactivated TP53 allele (see IARC TP53 database). As 
pointed out in Pfeifer and Besaratinia [11] large-scale genome 
sequencing of cancer genomes has revealed some interesting results 
not evident in TP53 patterns [55,56]. Thus there is a quantitative 
difference evident between strand-biased mutation patterns in TP53 
in breast cancers (Table 2A) compared with available data from   36 
genome-wide exome sequencing of breast cancer genomes [55,56]. 
In Table 8 are displayed data illustrating this difference [55] from the 
sequencing of exons of close to 20,000 protein coding genes in 
eleven breast cancer genomes. In the majority of these breast 
cancers (10/11) TP53 is mutated ( see supp data in [55]). 
  Note first, the strand biased pattern at A:T base pairs in TP53 
(Table 2A) and in genome-wide data (Table 8) are similar. The 
systematic A>>T and prominent A-to-G strand biases are evident. 
However in this data set (~1445 point mutations) the strand biases 
at G:C for G>>C  is systematic and just significant at the  P<0.05 
level. A key difference pointed out by Pfeifer and Besaratinia [11] is 
the higher load of mutations for G-to-C/C-to-G. Pfeifer and 
Besaratinia postulate: 
  "These data suggest that breast cancers are caused by an 
  etiological agent that induces this particular type of mutation. 
  There are few known mutagens that specifically induce G/C to 
  C/G transversions, let alone selectively at a particular 
  dinucleotide sequence." 
They then go on to point out that a significant fraction of these G to C 
transversions occur at the 5' GpA dinucleotide motif which is 5' TpC 
on the other strand.  
  From our perspective it is interesting that this happens to be 
the favoured APOBEC1 motif if this DNA deaminase enzyme, now   37 
unregulated, deaminated cytosines at such sites ([8] and see 
previous section, Table 7). Inspection of the TP53  "All Breast Cancer" 
data reveals there are indeed several 5'GpA sites which account for 
about a third of the load of G-to-C mutations in the strand-biased G-
to-C pattern in TP53 in cancers of the breast (Table 2A). These G-to-
C hotspots are at codons 196, 280 and 281 (Table 7) and constitute 
25 of 92 (27%) of all G-to-C mutations over codons 150-300 
inclusive.  Additionally, ten G-to-C mutations in this region occur at a 
CGC site in codon 156 (a motif favoured by AID deamination on the 
opposite strand). 
  Recently the Cancer Genome Project (CGP) at The Welcome 
Trust Sanger Institute have reported on the exomic mutation 
spectrum of category-selected sets of 21 breast cancer genomes, 
Nik-Zainal et al [57]. Few if any significant strand biases are reported 
in this genome-wide data. Of real interest is the fact that only a 
minor fraction (4/21) carry an exomic mutation in TP53 and most 
sample sizes for mutations are statistically small ( N values in the 
hundreds)  - except tumor PD4120a which carries 1931 exomic 
mutations which are predominantly focused on G/C  with !5% 
mutations at A/T base pairs. Two of the tumors bearing a TP53 
mutation, PD4109a  and PD4199a, display the early trends of the 
significant strand biases at A:T and G:C base pairs (Table 9) evident 
in the earlier Woods et al 2007 exome study [55].    38 
  Collectively these genome-wide data sets suggest that 
mutations in TP53 accentuate strand-biased mutation patterns across 
the cancer genome implying that inactivated TP53 and dysregulated 
SHM contribute to such patterns. This conclusion is underlined by the 
documented functional interaction between TP53 and the Ig SHM 
machinery shown in mice by the Storb group, particularly in relation 
to the accentuated strand-biased mutation pattern of A-to-G versus 
T-to-C [49]. 
 
INFLAMMATION AND CARCINOGENSIS  
 
Whilst there are some exceptions and qualifications, we conclude that 
there is a strong statistically significant similarity between the strand-
biased mutation signatures of TP53 in many tumor types and the now 
well established Ig SHM pattern, particularly in relation to the strand 
biases of A-to-G over T-to-C and the G-to-A over C-to-T. Previous 
work on Ig SHM suggest that the A-to-G over T-to-C stand bias 
correlates strongly with A-to-I RNA editing coupled to reverse 
transcription to fix the A-to-G pattern in the cellular DNA [24]. 
  The G-to-A over C-to-T pattern is found to be a dominant 
strand bias in all those cancers arising in tissues "least accessible to 
tobacco smoke" suggesting that this strand biased pattern (as well as 
A-to-G over T-to-C) arises from endogenous mutation processes in   39 
most non-lymphoid cancers.  We have previously concluded that the 
G-to-A over C-to-T strand bias is consistent with RNA mutations 
initiated at C-sites by activation-induced cytidine deaminase (AID)-
mediated C-to-U deamination on the transcribed strand (TS) resulting 
in G-to-A transitions in the mRNA which are fixed as G-to-A 
mutations on the non-transcribed strand (NTS) following reverse 
transcription [5] and see Figure 1.  
  The present analyses therefore confirm and extends our earlier 
conclusions in a preliminary study of genome-wide somatic mutation 
data curated by the Cancer Genome Project (CGP) at The Welcome 
Trust Sanger Institute, Hixton, UK: [6].  The special features of the 
strand biases at A:T and G:C base pairs in tumors bearing mutated 
derivatives of TP53 imply a role for base-modified mRNA template 
intermediates and reverse transcription in somatic mutagenesis 
leading to or initiating cancer. In addition our analysis and 
conclusions are consistent with the view that inflammatory infiltrates, 
or in situ inflammatory episodes, in non-lymphoid tissues may 
contribute to dysregulated Ig SHM and thus oncogenesis, first by 
mutating components of the Ig SHM machinery and then by affecting 
mutations in TP53. This could occur via "a bystander effect" of 
various liberated cytokines inappropriately activating gene expression 
pathways in nearby non-lymphoid cells.  It is common clinical   40 
knowledge that most tumors have associated inflammatory infiltrates 
and are part and parcel of tumor growth.  
  This analysis also identifies several potential new drug targets 
for cancer therapy: in addition to AID and APOBEC family deaminases 
we can include Pol-!, ADAR1 and yet to be identified factors that 
modulate the apparatus of RNA Pol II transcription-coupled repair. 
Further, identifying the interacting proteins/genes mediating the 
functional TP53-Ig SHM interaction must also be considered a top 
priority in drug development and targeting. 
  Consistent with these conclusions is the large and now rapidly  
growing literature on chronic inflammation preceding cancer in many 
tissues [58]. Whilst it may not be possible to control all those induced 
somatic genetic factors leading to cancer, strategies to dampen and 
avoid chronic or transient inflammatory episodes in life may depress 
the chance of triggering "endogenous" mutagenic events, via 
dysregulated Ig SHM machinery, being turned on in non-lymphoid 
tissues [6]. This is particularly important in breast and ovarian tissues 
as estrogen can directly elevate AID expression as demonstrated by 
Petersen-Mahrt and colleagues [59-61].  Indeed the Pauklin et al 
data [60] show that estrogen induces AID transcription in these non-
lymphoid tissues suggesting that the TP53 G-site mutation hotspots 
in breast cancers may be directly caused by AID and other APOBEC-
family deaminases targeting such sites, as the data in Table 7 imply.   41 
Collectively, these findings and the present analyses are shedding a 
new light on how we might view oncogenesis. Our work points to the 
unregulated Ig SHM mechanism as playing a key role in the 
progression of the main non-lymphoid cancer groups. This provides 
us with a fundamentally new molecular model with which to view the 
process of oncogenesis, and ways to develop new strategies for 
treating (and perhaps preventing) the development of certain cancer 
groups. 
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Footnotes to Tables 
 
Table 1 
 
Data taken from Table 1 in [5]. Each entry is the mean percentage 
and standard error of the mean (shown in brackets) for each type of 
mutation rounded to one decimal place. All mutations scored from the 
coding or non-transcribed strand (NTS). Data in all studies were 
corrected for the base composition of the V region or 3' flanks 
assayed for mutations. In A, data averaged over twelve studies 
(n=12); in B, data averaged over twenty studies (n=20). Note that 
one study by Winter et al [20] inadvertently left out of the survey (   53 
see supplementary data in [5]) but its omission does not change the 
patterns documented in Table 1B. 
 
Table 2 
 
Values in A represent the % of the total of 2279 somatic point 
mutations scored in category "All Breast Cancers" (R15); values in B 
represent the % of the total of 1215 somatic point mutations scored 
in category  "All Bladder Cancers" (R15); values in C represent the % 
of  the total of 2471 somatic point mutations scored in category "All 
Lung Cancers" (R15). † The percentage base composition in the TP53 
coding region for codons 130-300 inclusive - the region which 
contains the vast majority of mutations spanning the DNA binding 
region. The Chi-Squared statistics (significance levels) are essentially 
unaltered if mutation frequencies are corrected for base composition. 
The breakdown of G-to-A and C-to-T mutations at CpG and non-CpG 
sites is as follows: In A. for C-to-T mutations 199 occur at CpG sites 
and 267 occur at non-CpG sites. For G-to-A 320 occur CpG and 387 
occur at non-CpG sites. In B. for C-to-T 104 occur at CpG sites and 
126 occur at non-CpG sites. For G-to-A 153 occur at CpG sites and 
265 occur at non-CpG sites. In C.  for C-to-T 209 occur at CpG and 
173 occur at non-CpG sites. For G-to-A 214 occur at CpG and 154 
occur at non-CpG sites.   54 
 
 
Table 3  
 
Values in the table represent the % of the total of 1575 somatic point 
mutations scored in category "All Ovary" (R15). † The percentage 
base composition in the TP53 coding region for codons 130-300 
inclusive - the region which contains the vast majority of mutations 
spanning the DNA binding region. The Chi-Squared statistics 
(significance levels) are essentially unaltered if mutation frequencies 
are corrected for base composition. Note for C-to-T mutations 122 
are at non-CpG and 183 are at CpG sites; for G-to-A mutations 222 
are at non-CpG and 260 are at CpG sites. 
 
Table 4 
 
† All experimental mouse studies except work in cells from human 
Xeroderma Pigmentosium Variant (XPV) patients with genetic 
deficiency in DNA polymerase ! (eta), Zeng et al [45]. UNG, uracil 
DNA glycosylase, removes uracil from DNA generating an abasic site; 
MSH2, MSH2 protein component of MSH2-MSH6 mismatch repair 
heterodimer; Pol!, DNA polymerase eta, Y family polymerase ; Pol", 
DNA polymerase kappa, Y family polymerase; Pol#, DNA polymerase 
iota, Y family polymerase; "-/-", homozygous deficiency (gene knock-  55 
out mouse line); ¶ Aag, alkyladenine DNA glycosylase which removes 
hypoxanthine (deaminated adenine) from DNA generating an abasic 
site; § Ogg1, 8-hydroxyguanine-DNA glycosylase which removes 
oxidised guanine ("8oxoG") from DNA thus generating an abasic site. 
Not shown are two additional deficiencies : (a) The affect of Rev1 
deficiency which affects G-to-C mutations as Rev1 plays a special and 
limited role in SHM by inserting dC opposite dU and abasic sites in 
VDJ DNA carrying AID-induced lesions, Jansen et al [50] and Steele 
[5] (member of Y family polymerase family) ) ;  and (b) The effect of 
DNA polymerases zeta (-$) deficiency where studies show Pol-$ plays 
a special role in SHM by generating the observed low frequency 
tandem mutations in immunoglobulin variable regions, Saribasak et 
al [51]. C>>G. mutations off C exceed mutations off G by ratio 
indicated; A>>T, mutations off A exceed mutations off T by ratio 
indicated. 
 
Table 5 
 
Values in A represent the % of the total of 1553 somatic point 
mutations scored in category "All Colorectum Cancers" (R15) ; values 
in B represent the % of the total of 844 somatic point mutations 
scored in category  "All Stomach Cancers" (R15); values in C 
represent the % of  the total of 789 somatic point mutations scored   56 
in category "All Skin Cancers" (R15). † The percentage base 
composition in the TP53 coding region for codons 130-300 inclusive - 
the region which contains the vast majority of mutations spanning 
the DNA binding region. The Chi-Squared statistics (significance 
levels) are essentially unaltered if mutation frequencies are corrected 
for base composition. The breakdown of G-to-A and C-to-T mutations 
at CpG and non-CpG sites is as follows: In A. for C-to-T mutations 
328 occur at CpG sites and 93 occur at non-CpG sites. For G-to-A 489 
occur CpG and 186 occur at non-CpG sites. In B. for C-to-T 145 occur 
at CpG sites and 87 occur at non-CpG sites. For G-to-A 180 occur at 
CpG sites and 90 occur at non-CpG sites. In C.  for C-to-T 97 occur at 
CpG and 217 occur at non-CpG sites. For G-to-A 44 occur at CpG and 
123 occur at non-CpG sites. 
 
Table 6 
 
Values in the table represent the % of the total of 748 somatic point 
mutations scored in category "Glioblastoma" (R15). † The percentage 
base composition in the TP53 coding region codons 130-300 inclusive 
- the region which contains the vast majority of mutations spanning 
the DNA binding region. The Chi-Squared statistics (significance 
levels) are essentially unaltered if mutation frequencies are corrected 
for base composition. Note for C-to-T mutations 57 are at non-CpG   57 
and 174 are at CpG sites; for G-to-A mutations 89 are at non-CpG 
and 154 are at CpG sites 
 
Table 7 
 
a. Only G-sites with #5 mutations listed 
b. NTS, non-transcribed strand; TS, transcribed strand     
c. From Beale et al 2004 Table 2 [8]. ?, indicates that first two bases 
in TS motif consistent with deamination target in [8]. 
 
Table 8 
 
Values in the table represent the % of the total of 1445 somatic point 
mutations scored over the exons of 11 individual breast cancer 
genomes comprising ~ 20,000 protein coding genes Wood et al [48]. 
The very low number of ambiguous and heterozygote double 
mutation data not included.  The Chi-Squared statistics (significance 
levels) are indicated as in previous tables.  
 
Table 9  
From Exome Supplementary Data from Nik-Zainal et al 2012 [57]. 
The numbers in the table are the number of mutations scored. N = 
total number of exomic mutations.   58 
 
 
 
 
 
 
Legend to Figure 1.  
 
Explanation for TP53 strand biased mutations in the 
"Endogenous Patterns" outlined in the text based on the 
reverse transcriptase model of Ig SHM viz. transcription-
coupled DNA and RNA deamination followed by reverse 
transcription Adapted and modified from Figure 5 in Steele 2009 [5]  
following Steele and Lindley 2010 [6]. Shown are some hypothesised 
DNA and RNA intermediates highlighted for the generation of the 
main strand- biased mutation signatures involving A-to-G, G-to-A, G-
to-T and G-to-C. Black lines are DNA strands, red lines are mRNA, 
blue lines are cDNA strands copied off mRNA by a cellular reverse 
transcriptase such as DNA polymerase !. Steps A. through D. show 
various mutated DNA and RNA intermediates and substrate 
complexes for both deamination reactions, 8oxoG modifications in 
RNA , Wu and Z. 2008 [22] and cDNA synthesis (it is not known if 
8oxoG sites are preferred in unpaired loops or dsRNA regions). In 
over view, mutations are first introduced at the DNA level by 
AID/APOBEC family-mediated C-to-U deaminations and then uracil   59 
DNA glycosylase (UNG)-generated abasic sites in the TS (which can 
further mature into single strand nicks via the action of AP 
endonuclease (APE1). These template sites are transcribed into 
mRNA by RNA Pol II generating G-to-A and G-to-C modifications 
respectively in the mRNA , Kuraoka et al, 2003 [23] which on reverse 
transcription, integration and DNA replication result in G-to-A and G-
to-C mutations in the NTS. Separately adenosine-to-inosine (A-to-I) 
RNA editing events at WA targets in the nascent ds mRNA stem loops 
may be copied back into DNA by reverse transcription via Pol-! , 
Franklin et al, 2004 [17]. Also shown are 8oxoG modifications in 
mRNA which on reverse transcription, integration and DNA replication 
would result in strand-biased G-to-T transversions on the NTS.   The 
strand invasion (?) and integration of newly synthesised cDNA TS (?) 
are hypothesized necessary steps. In more detail: A. RNA Pol II 
introduces mutations in mRNA as it copies the AID/APOBEC lesions in 
TS DNA [22], concurrently A-to-I RNA edited sites appear in RNA 
stem(-loops) forming in nascent mRNA near the transcription bubble 
[Steele et al., 2006 [24] or 8oxoG modifications via reactive oxygen 
species [22]. B. Formation of RT-priming substrate (DNA polymerase-
!) by annealing of nicked TS strand with an exposed 3'-OH end. This 
could arise due to excision at a previous AID-mediated abasic site or 
an excision introduced by endonuclease activity associated with the 
MSH2-MSH6 heterodimer engaging a U:G mispaired lesion. C.   60 
Extension of new TS by cDNA synthesis from the 3'-OH end copying 
the already base modified mRNA template (with I base pairing 
preferentially, like G, with C; and 8oxoG mispairing with A).  D. Then 
an unknown and indeterminant number of steps involving strand 
invasion(?), heteroduplex formation and/or resolution of heteroduplex 
(?), full length copying of newly synthesized transcribed strand (?) 
cDNA.  
 
Legend to Figure 2 
 
A-to-G spectrum in TP53 for  All Lung Cancers versus All 
Breast Cancers Covering A-sites in TP53 from codon 100 to 300 
inclusive. The Pearson correlation coefficient (r) is 0.93, which for 
129 degrees of freedom gives a P<0.001. 
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Appendix : Detection of Strand-Biased Somatic Mutation Signatures. 
In a data set containing a large number of somatic mutations strand 
biased signatures are revealed by comparing the base substitution 
frequencies of Watson-Crick complements on the same strand. By 
convention nucleotide substitutions are read from the non-transcribed 
strand (NTS). However the known direction of transcription in a 
region of genomic DNA encoding a protein allows identification of the 
strands. Thus if A-to-G mutations occur with equal frequency on both 
strands, then its Watson-Crick complement, T-to-C will occur with 
equivalent frequency when scored off the same strand. However if 
there is a bias in the mutations favouring the NTS then A-to-G 
mutations will exceed T-to-C mutations. If there are systematic 
strand biases involving excessive mutations of A or G (e.g. as seen in 
many of the data tables presented herein) then the sum total of 
mutations of A will exceed the sum total of mutations of T (at A:T 
base pairs where A>>T) and the sum total of mutations of G will 
exceed the sum total of mutations of C (at G:C base pairs where 
G>>C). 
 
 
 
 
 
 
 
 
 
Transcribed Strand - TS 
5'   3'  
A-to-G  
Non-Transcribed Strand - NTS 
5'   3'  
A-to-G   T-to-C  
T-to-C  
Replication   Replication  Table 1 Typical patterns of somatic point mutations observed at rearranged 
immunoglobulin variable region loci in mice   
 
A. Studies where PCR recombinant artefacts in DNA sequence data absent or minimized 
 
       Mutant Base            ,   
Original  _____________________________________________         
Base    A    T    C    G    Total        
                     
  A     -          10.6 (1.2)  6.3 (0.9)  14.6 (0.7)  31.6 (1.7)      
                             
  T    3.1 (0.6)   -    5.3 (1.1)   2.6 (0.6)  11.0 (1.3)      
                      
  C    4.3 (0.8)  13.4 (1.3)     -   3.6 (0.7)  21.3 (1.3)      
                             
  G     20.1 (1.9)    7.2 (1.4)  8.7 (0.7)    -  36.1 (2.5)   
 
B. Studies where PCR recombinant artefacts in DNA sequence data were not minimized 
 
       Mutant Base            ,   
Original  _____________________________________________         
Base    A    T    C    G    Total        
                     
  A     -           9.9 (0.5)  7.3 (0.5)  16.5 (0.5)  33.7 (0.7)      
                             
  T    5.4 (0.3)   -    9.0 (0.5)   3.6 (0.3)  18.0 (0.6)      
                      
  C    3.7 (0.3)  15.0 (0.8)     -   5.9 (0.6)  24.6 (1.0)      
                             
  G     14.4 (0.6)    4.2 (0.4)  6.5 (0.7)    -  24.4 (0.7)   
 
 
 
 
 
 
                  
 Table 2 Somatic Point Mutation Patterns in the TP53 coding region in  
"All Breast Cancers", "All Bladder Cancers" and "All Lung Cancers". 
 
A. All Breast Cancers 
   
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A (22%)†   -   2.6  1.9  11.0  15.5    A>>T    1.3x   P<0.05   
                           
T (21%)  3.1    -  4.8   3.9  11.8    A>G v T>C  2.3x  P<0.001   
                -------------------------------     
C (29%)  2.8  20.4   -   3.6  26.8    G>>C    1.7x   P<0.001   
                           
G (28%)    31.0     9.3  5.5   -  45.9    G>A v C>T  1.5x  P<0.001 
                G>T v C>A  3.3x  P<0.001 
                G>C v C>G 1.5x  P<0.05 
B. All Bladder Cancers 
 
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A (22%)†   -   3.1  1.4   9.6  14.1    A>>T    2.5x   P<0.001   
                           
T (21%)  1.8    -  1.7   2.2    5.7    A>G v T>C  5.8x  P<0.001   
                -------------------------------     
C (29%)  2.9  18.9   -   5.2  27.0    G>>C    2.0x   P<0.001   
                           
G (28%)    34.4    9.5  9.3   -  53.3    G>A v C>T  1.8x  P<0.001 
                G>T v C>A  3.3x  P<0.001 
                G>C v C>G 1.8x   P<0.01 
C. All Lung Cancers 
 
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A (22%)†   -   5.4  1.6  10.3  17.3    A>>T    2.5x   P<0.001   
                           
T (21%)  2.1    -  2.3   2.5    6.9    A>G v T>C  4.5x  P<0.001   
                -------------------------------   
C (29%)  3.1  15.5   -   5.0  23.9    G>>C    2.2x   P<0.001   
                           
G (28%)    14.9  30.4  7.0   -  52.2    G>A v C>T  1.0  NS     
                G>T v C>A  12.1x P<0.001 
                G>C v C>G 1.4x   P<0.05 
_________________________________________________________________     
 
 Table 3 Somatic Point Mutation Patterns in the TP53 coding region in  
"All Ovary" cancers 
 
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A (22%)†   -   2.1  1.6  13.0  16.7    A>>T    1.6x   P<0.001   
                           
T (21%)  2.9    -  4.1   3.3  10.3    A>G v T>C  3.2x  P<0.001   
                -------------------------------     
C (29%)  2.1  19.4   -   4.6  26.1    G>>C    1.8x   P<0.001   
                           
G (28%)    30.6   12.3  3.9   -  46.9    G>A v C>T  1.6x  P<0.001 
                G>T v C>A  5.9x  P<0.001 
                G>C v C>G 0.9x  NS 
_________________________________________________________________     Table 4 Affect of main DNA repair deficiencies in Ig somatic hypermutation 
studies in mice 
 
Gene-protein             Affect on frequency of: 
deficiency†      A/T mutations      G/C mutations     References 
______________________________________________________________________________ 
 
UNG-/-      15% suppression      95% C-to-T/G-to-A      [43] 
        (A>>T strand bias) 
 
UNG-/-MSH2-/-    98% suppression      >99.5% C-to-T/G-to-A    [44] 
                  (C>>G 1.5x P<0.001)    See [5] 
 
Pol !-/-      70% suppression      No change (enriched in     [45]† 
        (residual A>>T)      expected proportion)    [18] 
 
Pol "-/-      No change        No change        [46] 
 
Pol #-/-      No change        No change        [47] 
 
Pol !-/-Pol "-/-    87% suppression      No change (enriched in    [19] 
        (residual A>>T)      expected proportion) 
 
MSH2-/-      80% suppression      >80% C-to-T/G-to-A    [18] 
        (residual A>>T ?)      (C>>G 1.5x P<0.05)   
 
Pol !-/-MSH2-/-    >99% suppression     >85% C-to-T/G-to-A    [18] 
                  (C>>G 1.5x P<0.001) 
 
Ogg1 (-/-)§      No change        No change        [20] 
 
 
Aag (-/-)¶      No affect on A-to-G    No change        [48] 
        mutation frequency. 
        Slight statistically significant 
        increase in T-to-C and thus  
        slight reduction in A>>T  
        strand bias. 
 
 
p53 (-/-)      56% increase in A-to-G    Decreased G-to-A.     [49] 
        (increased A>>T       Enhanced G-to-C v C-to-G 
        strand bias)       ratio and thus strand bias. 
______________________________________________________________________________
   
 Table 5 Somatic Point Mutation Patterns in the TP53 coding region in  
"All Colorectum Cancers", "All Stomach Cancers" and "All Skin Cancers". 
 
A. All Colorectum Cancers 
 
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A (22%)†   -   2.0  0.8   4.6   7.4    A>>T    1.0x   NS     
                         
T (21%)  1.9    -  3.7   2.0   7.7    A>G v T>C  1.2x  NS     
              -------------------------------     
C (29%)  2.1  27.1   -   2.2  31.4    G>>C    1.7x   P<0.001   
                           
G (28%)    43.5     7.5  2.6   -  53.6    G>A v C>T  1.6x  P<0.001 
                G>T v C>A  3.7x  P<0.001 
                G>C v C>G 1.2x  NS 
B. All Stomach Cancers 
 
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A (22%)†   -   2.3  1.9   7.3  11.5    A>>T    1.2x   NS     
                         
T (21%)  3.8    -  4.0   2.3  10.0    A>G v T>C  1.8x  P<0.05   
                -------------------------------     
C (29%)  3.6  27.5   -   3.9  35.00   G>>C    1.2x   P<0.05   
                           
G (28%)    32.5    7.7  3.3   -  43.4    G>A v C>T  1.2x  NS 
                G>T v C>A  2.2x  P<0.05 
                G>C v C>G 0.9x   NS 
C. All Skin Cancers 
 
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A (22%)†   -   3.3  1.4   5.2   9.9    A>>T    0.9x   NS     
                         
T (21%)  2.4    -  6.2   3.0  11.7    A>G v T>C  0.8x  NS     
                           
C (29%)  3.2  39.8   -   2.8  45.8    C>>G    1.4x   P<0.01   
                           
G (28%)    21.2    7.0  4.6   -  32.7    C>T v G>A  1.9x  P<0.001   
                G>T v C>A  2.2x P<0.05 
                G>C v C>G 1.6x   NS 
_________________________________________________________________     
 Table 5 Somatic Point Mutation Patterns in the TP53 coding region in  
"Glioblastoma" cancers of brain 
 
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A (22%)†   -   1.5  1.5   8.6  11.5    A>>T    1.6x   NS     
                         
T (21%)  1.2    -  3.6   2.3    7.1    A>G v T>C  2.4x  P<0.01   
                -------------------------------     
C (29%)  3.2  30.9   -   3.6  37.8    G>>C    1.2x   NS     
                         
G (28%)    32.5     7.4  3.9   -  43.7    G>A v C>T  1.1x  NS 
                G>T v C>A  2.3x  P<0.05 
                G>C v C>G 1.1x  NS 
_________________________________________________________________     
 Table 7 Hotspots in breast cancers for G-site mutations in TP53 in relation 
to codon, target motif and likely dC-to-dU deaminase 
 
   
aNumber mutations:      
bMotif on:    
cLikely C>U  
Codon 
a  G>A  G>T  G>C    NTS    TS    DNA deaminase 
 
156    1  0      10    CGC    GCG    AID 
157    0  8  0    CGT    ACG    AID 
158    2  1  2    CGC    GCG    AID 
173    7  8  3    TGT    ACA    AID 
175        128  2  1    CGC    GCG    AID 
176    6      10  1    TGC    GCA    AID 
181    3  1  2    CGC    GCG    AID 
196    2  0  5    CGA    TCG    APOBEC1? 
216         12  3  0    TGT    ACA    AID 
237         17  7  3    TGT    ACA    AID 
238           13  6  1    TGT    ACA    AID 
242    7  6  1    TGC    GCA    AID 
243    5  1  2    TGG    CCA    APOBEC3G? 
244           10  0  1    GGG    CGC    APOBEC3G? 
244    8  2  0    GGC    GCC    AID 
245           38  3  1    CGG    CCG    APOBEC3G 
245           14  3  1    GGC    GCC    AID 
248         104  7  2    CGG    CGG    APOBEC3G 
249    4  1  0    AGG    CCT    APOBEC3G? 
249    1  14  2    GGC    GCC    AID 
258    3  1  1    GGA    TCC    APOBEC1? 
266    2  2  3    GGG    CCC    APOBEC3G? 
266         10  4  0    GGA    TCC    APOBEC1 
272         10  1  0    GGT    ACC    AID 
273           93  5  5    CGT    ACG    AID 
275    8  7  0    TGT    ACA    AID 
277    2  4  0    TGT    ACA    AID 
280    7  1      14    AGA    TCT    APOBEC1? 
281    5  0  6    AGA    TCT    APOBEC1?   
282    1  3  3    CGG    CCG    APOBEC3G 
283    3  0  3    CGC    GCG    AID 
285          21  1  0    AGA    TCT    APOBEC1? 
286    9  0  0    GGA    TCC    APOBEC1? 
294    0  5  0    GGA    TCC    APOBEC1? 
 
.                            .  
 
 Table 8 Somatic point mutation patterns in breast cancer derived from 
large-scale exomic sequencing of breast cancer genomes 
 
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A      -   4.3  3.0   6.0  13.4    A>>T    1.7x   P<0.01   
                           
T     2.7    -  3.5   1.7    7.8    A>G v T>C  1.7x  P<0.05   
                -------------------------------     
C     7.8  16.2   -   11.9  35.9    G>>C    1.2x   P<0.05   
                           
G          19.7     9.1  14.1   -  42.9    G>A v C>T  1.2x  NS 
                G>T v C>A  1.2x  NS 
                G>C v C>G 1.2x  NS 
_________________________________________________________________   
 
 Table 9 Somatic Point Mutation Patterns in the TP53 mutated Breast 
Cancers in Nik-Zainal et al exomic data [57]. 
 
PD3890a Brac1 N= 104   
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A     -  4  5  3  12    A>>T     NS       
                       
T    3    -  5  7  15    A>G v T>C   NS       
                -------------------------------     
C    10  19   -  10    39    G>>C     NS       
                       
G    13  7  18   -  38    G>A v C>T   NS 
                G>T v C>A   NS 
                G>C v C>G   NS 
PD4005a Brac1 N= 125   
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A     -  2  6  5  13    A>>T     NS       
                       
T    6    -  8  5  19    A>G v T>C   NS       
                -------------------------------     
C    7  24   -  17    48    G>>C     NS       
                       
G    22  10  13   -  45    G>A v C>T   NS 
                G>T v C>A   NS 
                G>C v C>G   NS 
PD4109a Triple Negative N= 174   
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A     -  11  5  11  27    A>>T    1.35x  NS      
                         
T    7    -  7  6  20    A>G v T>C  1.57x   NS     
                  ------------------------------- 
   
C    8  25   -  20    53    G>>C     1.4x    NS     
                         
G    33  18  23   -  74    G>A v C>T   1.32x  NS 
                G>T v C>A   2.25x  NS 
                G>C v C>G   1.15x  NS 
PD4199a ER-ve, HER2 +ve N= 156  
       Mutant Base            ,   
Original  _________________________          
Base    A  T  C  G  Total    Statistics:         
               
A     -  1  2  4  7    A>>T     NS       
                       
T    1    -  3  1  5    A>G v T>C   NS       
                -------------------------------     
C    6  23   -  19    48    G>>C     2.0x  P<0.01   
                           
G    56  8  32   -  96    G>A v C>T   2.43x P<0.05 
                G>T v C>A   1.33x  NS 
                G>C v C>G   1.68x  NS  
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Figure 2  
A-to-G spectrum in All Lung Cancers versus All Breast Cancers covering A-sites in TP53 from codon 100 to 300 inclusive. The 
Pearson correlation coefficient (r) is 0.93, which for 129 degrees of freedom gives a P<0.001. 
 